Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (63582) 63582
Newspaper Article (12036) 12036
Newsletter (4604) 4604
Book Chapter (1493) 1493
Web Resource (814) 814
Magazine Article (307) 307
Trade Publication Article (172) 172
Book / eBook (89) 89
Dissertation (71) 71
Transcript (56) 56
Publication (28) 28
Conference Proceeding (18) 18
Book Review (14) 14
Reference (10) 10
Report (5) 5
Government Document (4) 4
Journal / eJournal (3) 3
Paper (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47606) 47606
science & technology (45220) 45220
life sciences & biomedicine (43530) 43530
lymphoma (30987) 30987
male (24978) 24978
oncology (24033) 24033
female (23841) 23841
hematology (20328) 20328
middle aged (18484) 18484
cancer (15642) 15642
lymphomas (15475) 15475
adult (15458) 15458
aged (15187) 15187
biological and medical sciences (14989) 14989
medical sciences (14837) 14837
chemotherapy (11233) 11233
hematologic and hematopoietic diseases (11030) 11030
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (10766) 10766
leukemia (9556) 9556
care and treatment (9072) 9072
research (8858) 8858
prognosis (8702) 8702
tumors (8287) 8287
antineoplastic combined chemotherapy protocols - therapeutic use (8245) 8245
treatment outcome (7605) 7605
non-hodgkin's lymphomas (7429) 7429
animals (6954) 6954
patients (6757) 6757
adolescent (6712) 6712
aged, 80 and over (6160) 6160
apoptosis (5677) 5677
clinical trials (5594) 5594
cancer therapies (5507) 5507
rituximab (5416) 5416
hemic and lymphatic diseases (5267) 5267
child (5215) 5215
health aspects (5206) 5206
abridged index medicus (5123) 5123
medical research (4878) 4878
antineoplastic agents (4812) 4812
immunotherapy (4669) 4669
lymphoma, large b-cell, diffuse - drug therapy (4655) 4655
analysis (4639) 4639
medicine & public health (4537) 4537
antineoplastic agents - therapeutic use (4505) 4505
retrospective studies (4425) 4425
pathology (4272) 4272
proteins (4228) 4228
mice (4108) 4108
lymphocytes (4092) 4092
gene expression (4054) 4054
genetic aspects (4015) 4015
lymphoma, large b-cell, diffuse - pathology (3973) 3973
t cells (3895) 3895
lymphocytes b (3774) 3774
immunology (3753) 3753
drug therapy (3707) 3707
cell line, tumor (3705) 3705
stem cells (3643) 3643
diagnosis (3621) 3621
risk factors (3576) 3576
young adult (3576) 3576
child, preschool (3381) 3381
transplantation (3347) 3347
immunohistochemistry (3342) 3342
medical prognosis (3324) 3324
pharmaceutical industry (3249) 3249
disease-free survival (3227) 3227
biopsy (3203) 3203
multiple myeloma (3097) 3097
bone marrow (3084) 3084
antigens (3081) 3081
combined modality therapy (3017) 3017
mutation (2995) 2995
neoplasm staging (2991) 2991
medicine (2977) 2977
lymphoma, b-cell - pathology (2955) 2955
follow-up studies (2890) 2890
studies (2875) 2875
pediatrics (2874) 2874
lymphoma, b-cell - drug therapy (2858) 2858
b-cell lymphoma (2849) 2849
flow cytometry (2838) 2838
cyclophosphamide - administration & dosage (2788) 2788
kinases (2782) 2782
pharmacology. drug treatments (2747) 2747
survival analysis (2711) 2711
survival rate (2697) 2697
fda approval (2693) 2693
diagnosis, differential (2674) 2674
lymphoma, non-hodgkin - drug therapy (2637) 2637
immune system diseases (2631) 2631
development and progression (2623) 2623
remission induction (2615) 2615
vincristine - administration & dosage (2597) 2597
recurrence (2542) 2542
antibodies, monoclonal - therapeutic use (2531) 2531
antineoplastic combined chemotherapy protocols - administration & dosage (2519) 2519
drug dosages (2495) 2495
antimitotic agents (2467) 2467
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (25) 25
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Online Resources - Online (4) 4
Scarborough Hospital - Online (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Scarborough Hospital - Hospital Department (2) 2
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (80535) 80535
Japanese (993) 993
German (615) 615
French (577) 577
Chinese (466) 466
Spanish (296) 296
Russian (260) 260
Italian (202) 202
Polish (102) 102
Portuguese (101) 101
Korean (69) 69
Hungarian (38) 38
Czech (30) 30
Danish (30) 30
Dutch (28) 28
Turkish (21) 21
Norwegian (16) 16
Croatian (15) 15
Serbian (14) 14
Romanian (10) 10
Finnish (8) 8
Hebrew (8) 8
Swedish (6) 6
Ukrainian (5) 5
Slovak (4) 4
Persian (3) 3
Lithuanian (2) 2
Breton (1) 1
Bulgarian (1) 1
Catalan (1) 1
Galician (1) 1
Greek (1) 1
Latvian (1) 1
Manx (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype
by Hernandez‐Ilizaliturri, Francisco J and Deeb, George and Zinzani, Pier L and Pileri, Stefano A and Malik, Farhana and Macon, William R and Goy, Andre and Witzig, Thomas E and Czuczman, Myron S
Cancer, ISSN 0008-543X, 11/2011, Volume 117, Issue 22, pp. 5058 - 5066
nongerminal center B‐cell–like lymphoma | relapsed/refractory | lenalidomide | Hans algorithm | diffuse large B‐cell lymphoma | germinal center B‐cell–like lymphoma | germinal center B-cell-like lymphoma | diffuse large B-cell lymphoma | nongerminal center B-cell-like lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Recurrence | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Germinal Center - pathology | Thalidomide - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Lymphoma, Large B-Cell, Diffuse - classification | Female | Aged | Thalidomide - therapeutic use | Care and treatment | Lymphomas | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
by Cardenas, Mariano G and Yu, Wenbo and Beguelin, Wendy and Teater, Matthew R and Geng, Huimin and Goldstein, Rebecca L and Oswald, Erin and Hatzi, Katerina and Yang, Shao-Ning and Cohen, Joanna and Shaknovich, Rita and Vanommeslaeghe, Kenno and Cheng, Huimin and Liang, Dongdong and Cho, Hyo Je and Abbott, Joshua and Tam, Wayne and Du, Wei and Leonard, John P and Elemento, Olivier and Cerchietti, Leandro and Cierpicki, Tomasz and Xue, Fengtian and MacKerell, Alexander D and Melnick, Ari M
The Journal of clinical investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3351 - 3362
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Neoplasm Transplantation | Proto-Oncogene Proteins c-bcl-6 - antagonists & inhibitors | Translocation, Genetic | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Magnetic Resonance Spectroscopy | Humans | Gene Expression Regulation, Neoplastic | Male | Mice, SCID | Animals | Proto-Oncogene Proteins c-bcl-6 - metabolism | Drug Design | HEK293 Cells | Cell Line, Tumor | Protein Binding | Indoles - pharmacology | Ligands | Antineoplastic Agents - pharmacology | Mice | Thiazolidinediones - pharmacology | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Physiological aspects | Care and treatment | Usage | Lymphomas | Enzyme inhibitors | B cells | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text B‐cell receptor signalling and its crosstalk with other pathways in normal and malignant cells
by Seda, Vaclav and Mraz, Marek
European journal of haematology, ISSN 0902-4441, 03/2015, Volume 94, Issue 3, pp. 193 - 205
LYN | ibrutinib | B cell | PIK | spleen tyrosine kinase | ZAP‐70 | NFκB | bruton tyrosine kinase | miRNA | B‐cell receptor | ZAP-70 | Bruton tyrosine kinase | Spleen tyrosine kinase | MiRNA | B-cell receptor | Ibrutinib | Life Sciences & Biomedicine | Hematology | Science & Technology | Lymphoma, Follicular - metabolism | Lymphoma, Follicular - drug therapy | Protein-Tyrosine Kinases - metabolism | Humans | Antineoplastic Agents - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Lymphoma, Large B-Cell, Diffuse - metabolism | Receptors, Antigen, B-Cell - metabolism | Protein-Tyrosine Kinases - genetics | Lymphoma, Follicular - genetics | B-Lymphocytes - pathology | B-Lymphocytes - metabolism | Lymphoma, Large B-Cell, Diffuse - drug therapy | Receptor Cross-Talk | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Follicular - pathology | Receptors, Antigen, B-Cell - antagonists & inhibitors | Signal Transduction - genetics | Gene Expression Regulation, Leukemic | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | B-Lymphocytes - drug effects | Protein Kinase Inhibitors - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Receptors, Antigen, B-Cell - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Lymphoma, Large B-Cell, Diffuse - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | B cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Managing the front‐line treatment for diffuse large B cell lymphoma and high‐grade B cell lymphoma during the COVID‐19 outbreak
by de la Cruz‐Benito, Beatriz and Lázaro‐del Campo, Paula and Ramírez‐López, Andrés and de Soto‐Álvarez, Teresa and Sánchez‐Vadillo, Irene and García‐Pérez, Eduardo and Dos Santos‐Ortas, Abel and Humala‐Barbier, Karem and López‐de la Guía, Ana and Casado‐Abad, Gema and Jiménez‐Yuste, Victor and Canales‐Albendea, Miguel
British journal of haematology, ISSN 0007-1048, 11/2020, Volume 191, Issue 3, pp. 386 - 389
haematological malignancies | high‐grade | COVID‐19 | SARS‐CoV‐2 | B cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Hydroxychloroquine - therapeutic use | Superinfection - drug therapy | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Pandemics | COVID-19 Testing | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Infection Control - methods | Cyclophosphamide - adverse effects | Febrile Neutropenia - prevention & control | COVID-19 - prevention & control | Anti-Bacterial Agents - therapeutic use | Bacterial Infections - complications | SARS-CoV-2 | COVID-19 - complications | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | COVID-19 - epidemiology | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Antiviral Agents - therapeutic use | Bacterial Infections - drug therapy | Plasmablastic Lymphoma - drug therapy | Granulocyte Colony-Stimulating Factor - therapeutic use | COVID-19 - drug therapy | Rituximab - administration & dosage | Azithromycin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Spain - epidemiology | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Patients | Lymphoma | B-cell lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
by Kochenderfer, James N and Dudley, Mark E and Kassim, Sadik H and Somerville, Robert P. T and Carpenter, Robert O and Maryalice, Stetler-Stevenson and Yang, James C and Phan, Giao Q and Hughes, Marybeth S and Sherry, Richard M and Raffeld, Mark and Feldman, Steven and Lu, Lily and Li, Yong F and Ngo, Lien T and Goy, Andre and Feldman, Tatyana and Spaner, David E and Wang, Michael L and Chen, Clara C and Kranick, Sarah M and Nath, Avindra and Nathan, Debbie-Ann N and Morton, Kathleen E and Toomey, Mary Ann and Rosenberg, Steven A
Journal of clinical oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 6, pp. 540 - 549
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Immunotherapy, Adoptive - methods | Lymphoma, Large B-Cell, Diffuse - drug therapy | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Combined Modality Therapy | Vidarabine - analogs & derivatives | T-Lymphocytes - transplantation | Lymphoma, Large B-Cell, Diffuse - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell - immunology | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Receptors, Antigen, T-Cell - immunology | T-Lymphocytes - immunology | Aged | Vidarabine - administration & dosage | Transplantation Conditioning - methods | Antigens, CD19 - immunology | Lymphoma, B-Cell - drug therapy | Index Medicus | Hema17 | Hema8 | Hema16 | To6 | ORIGINAL REPORTS | Hema9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Anti-CD20 Antibody Therapy for B-Cell Lymphomas
by Maloney, David G
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 21, pp. 2008 - 2016
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Antigens, CD20 - immunology | Doxorubicin - therapeutic use | Humans | Middle Aged | Rituximab | Male | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Antibodies, Monoclonal, Murine-Derived - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, B-Cell - drug therapy | Practice Guidelines as Topic | Case studies | Medical case management | Monoclonal antibodies | Lymphomas | Dosage and administration | Drug therapy | Methods | Chemotherapy | Lymphocytes B | Immunotherapy | CD20 antigen | Antibodies | Cancer therapies | Lymphoma | Cancer | Abdomen | B-cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
by Neelapu, Sattva S and Locke, Frederick L and Bartlett, Nancy L and Lekakis, Lazaros J and Miklos, David B and Jacobson, Caron A and Braunschweig, Ira and Oluwole, Olalekan O and Siddiqi, Tanya and Lin, Yi and Timmerman, John M and Stiff, Patrick J and Friedberg, Jonathan W and Flinn, Ian W and Goy, Andre and Hill, Brian T and Smith, Mitchell R and Deol, Abhinav and Farooq, Umar and McSweeney, Peter and Munoz, Javier and Avivi, Irit and Castro, Januario E and Westin, Jason R and Chavez, Julio C and Ghobadi, Armin and Komanduri, Krishna V and Levy, Ronald and Jacobsen, Eric D and Witzig, Thomas E and Reagan, Patrick and Bot, Adrian and Rossi, John and Navale, Lynn and Jiang, Yizhou and Aycock, Jeff and Elias, Meg and Chang, David and Wiezorek, Jeff and Go, William Y
The New England journal of medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 26, pp. 2531 - 2544
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunotherapy, Adoptive | Interleukins - blood | Humans | Middle Aged | Receptors, Antigen, T-Cell - therapeutic use | Male | Survival Rate | Biomarkers - blood | T-Lymphocytes - transplantation | Lymphoma, Large B-Cell, Diffuse - mortality | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Receptors, Antigen, T-Cell - blood | Adult | Antigens, CD19 | Female | Nervous System Diseases - chemically induced | T-Lymphocytes - immunology | Aged | Neutropenia - chemically induced | Treatment outcome | Care and treatment | Lymphocytic leukemia | Analysis | Thrombocytopenia | CD19 antigen | Cytokines | Body weight | Clinical trials | Lymphocytes T | Patients | Cancer therapies | Lymphoma | Studies | Chimeric antigen receptors | Cyclophosphamide | Chemotherapy | Fludarabine | Lymphocytes B | Lymphocytes | Medical prognosis | Myelosuppression | Drug dosages | Neutropenia | B-cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights